VIR

VIR

USD

Vir Biotechnology Inc. Common Stock

$5.250-0.210 (-3.846%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$5.460

Hoch

$5.520

Tief

$5.200

Volumen

1.66M

Unternehmensfundamentaldaten

Marktkapitalisierung

729.3M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

1.44M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $4.155Aktuell $5.250Hoch $14.45

Ähnliche Nachrichten

BusinessWire

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2025, on November 5, 2025. The Company will

Mehr anzeigen
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
BusinessWire

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

– Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in combination with androgen receptor pathway inhibitors in first-line mCRPC – Clinical trial builds on

Mehr anzeigen
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
BusinessWire

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025

– Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart alone or in combination with elebsiran for chronic hepatitis delta to be presented – Vir Biotechnology to showcase progress in

Mehr anzeigen
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025